We have previously demonstrated that two years of adjuvant tamoxifen is effective for long-term breast cancer-related survival for patients with ER+ tumors from this trial [29], and that the effect of adjuvant tamoxifen therapy only seemed beneficial in patients with Luminal A tumors, as assessed by PAM50 [9]. The gene discussed is ESR1; the disease is breast carcinoma.